The AJMC® Migraine compendium is a comprehensive resource for clinical news and expert insights for the recurring type of headache, which is accompanied by side effects.
April 20th 2023
This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Migraine Prevalence May Be Associated With Spontaneous Coronary Artery Dissection
January 4th 2019Patients with a history of migraine are more likely to develop spontaneous coronary artery dissection at a younger age, have depression, and post-SCAD chest pains compared with patients without a migraine history, according to the results of a recent study.
Read More
Increased Monthly Migraine Days Associated With Higher Productivity Loss, Acute Medication Use
December 20th 2018Data from 3 erenumab clinical trials of patients with migraine have identified that an increase in the frequency of monthly migraine days leads to an increase in acute medication use and productivity loss.
Read More
Exmaning an assessment of data from the 2016 Global Burden of Diseases, Injuries, and Risk Factors study, researchers found that headache disorders, specifically migraine, are important causes of disability worldwide and therefore require more attention in health policy debates and greater resources for research.
Read More
Migraine With Aura Associated With Increased Risk of Atrial Fibrillation
December 5th 2018New research finds migraine with aura is associated with an increased risk of atrial fibrillation (AF), which may help provide a clearer picture of the relationship between the migraine subtype and cardioembolic stroke, as AF is a common source of cardioembolic stroke.
Read More
Experts Outline Migraine Treatment Choices for Elderly Patients
December 1st 2018A recent editorial outlined how to choose the necessary migraine pharmacotherapy for an elderly person and emphasized the importance of the careful personalization of treatment based on individual patient characteristics in order to choose a safe and effective migraine treatment.
Read More
Co-occurrence of Certain Migraine Symptoms Indicates a Common Pathophysiology
November 21st 2018Patients who have migraine often suffer from coexisting issues, such as sleep difficulties, vertigo, and dizziness. A study evaluating the presence of certain symptoms in patients with migraine indicated that some may have a common pathophysiology.
Read More
Genetic Risk Score May Be Effective for Predicting Migraine Response to Triptans
November 17th 2018Researchers tested the hypothesis that a genetic risk score based on single-nucleotide polymorphisms may influence headache response to triptans in patients and found a significant relationship between triptan efficacy and the cumulative score of genetic risk.
Read More
Headache Specialists Dissatisfied With Migraine Care in the ED
November 11th 2018Many headache specialists are not satisfied with the care their patients receive in the emergency department (ED), demonstrating the need for more standardized protocols for ED visits by patients with known headache disorders, according to a new study.
Read More
Review Evaluates Effects of Exogenous Estrogens and Progestogens on Migraine During Reproductive Age
November 3rd 2018As migraine is significantly more prevalent in women than men—likely due to fluctuations in estrogen levels—researchers conducted a systematic review of data involving the effect of exogenous estrogens and progestogens on the course of migraine during reproductive age, resulting in recommendations for clinical decision making.
Read More
Study Determines Link Between Migraine, ADHD in Adults
November 1st 2018Following indications of an association between migraine and attention deficit and hyperactivity disorder (ADHD) in children and adolescents, a new study has demonstrated a significant comorbidity of the 2 conditions in adults.
Read More
UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.
Read More